{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:00:07Z","timestamp":1782990007680,"version":"3.54.5"},"reference-count":14,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Positron-emission tomography (PET)-CT has recently been used for diagnostic imaging and radiotherapy for myeloid sarcoma, but there is little research on predicting the response of radiotherapy. The aim of this study was to analyze the association between PET-CT variables and the response to radiotherapy in patients with myeloid sarcoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This study was conducted in myeloid sarcoma patients who received radiotherapy and PET-CT before and after radiotherapy. The response to radiotherapy was evaluated based on the European Organization for Research and Treatment of Cancer PET response criteria, and binary regression analysis was performed to assess the factors predicting reductions in the maximum standardized uptake value (SUVmax).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-seven sites in 12 patients were included in the study. Complete metabolic responses were seen in 24 patients after radiotherapy, a partial metabolic response in one, and progressive metabolic disease in two patients. The prescribed dose of more than 3000 cGy\n                      <jats:sub>10<\/jats:sub>\n                      was significantly greater in the treatment control group (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.024). In binary logistic regression analysis predicting reductions in the SUVmax of more than 70% after radiotherapy, the pretreatment SUVmax (\u2265 7.5) and further chemotherapy after radiotherapy showed significant differences in univariate and multivariate analyses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Good metabolic responses (complete or partial) to radiotherapy were achieved in 92.6% of the myeloid sarcoma patients. Radiation doses &lt; 3000 cGy\n                      <jats:sub>10<\/jats:sub>\n                      and increased SUVmax were related to treatment failure and high SUVmax before radiotherapy was a factor influencing SUVmax reduction. Further large-scale studies are needed.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0261550","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T13:29:09Z","timestamp":1640006949000},"page":"e0261550","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Analysis of PET parameters predicting response to radiotherapy for myeloid sarcoma"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6446-6377","authenticated-orcid":true,"given":"Kyu Hye","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Ho","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoo-Kang","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong Seok","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,12,20]]},"reference":[{"key":"pone.0261550.ref001","first-page":"340","article-title":"A Case of Chloroma with Orbital Involvement Locally Benefited by X-Ray Therapy.","volume":"32","author":"C. King","year":"1934","journal-title":"Trans Am Ophthalmol Soc."},{"key":"pone.0261550.ref002","doi-asserted-by":"crossref","first-page":"20160710","DOI":"10.1259\/bjr.20160710","article-title":"Unravelling chloroma: review of imaging findings.","volume":"90","author":"A Singh","year":"2017","journal-title":"Br J Radiol"},{"key":"pone.0261550.ref003","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1200\/JCO.1997.15.2.466","article-title":"Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461.","volume":"15","author":"JC Byrd","year":"1997","journal-title":"J Clin Oncol."},{"key":"pone.0261550.ref004","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.clml.2017.02.027","article-title":"Myeloid Sarcoma: Presentation, Diagnosis, and Treatment.","volume":"17","author":"LM Almond","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"pone.0261550.ref005","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ijrobp.2018.05.045","article-title":"Use of Radiation in Extramedullary Leukemia\/Chloroma: Guidelines From the International Lymphoma Radiation Oncology Group","volume":"102","author":"RL Bakst","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"pone.0261550.ref006","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.ijrobp.2011.02.057","article-title":"Radiation therapy for chloroma (granulocytic sarcoma).","volume":"82","author":"R Bakst","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"pone.0261550.ref007","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/1471-2407-11-428","article-title":"Defining the optimal dose of radiation in leukemic patients with extramedullary lesions","volume":"11","author":"JH Song","year":"2011","journal-title":"BMC Cancer"},{"key":"pone.0261550.ref008","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2214\/AJR.11.7743","article-title":"Utility of FDG PET\/CT in the assessment of myeloid sarcoma.","volume":"198","author":"EY Lee","year":"2012","journal-title":"AJR Am J Roentgenol."},{"key":"pone.0261550.ref009","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","article-title":"Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations.","volume":"35","author":"European Organization for Research and Treatment of Cancer (EORTC) PET Study Group","year":"1999","journal-title":"Eur J Cancer"},{"key":"pone.0261550.ref010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/10245332.2017.1333275","article-title":"Clinical characteristics, molecular profile and outcomes of myeloid sarcoma: a single institution experience over 13 years.","volume":"23","author":"V Kaur","year":"2018","journal-title":"Hematology"},{"key":"pone.0261550.ref011","first-page":"192","article-title":"Effect of cytarabine, melphalan, and total body irradiation as conditioning for autologous stem cell transplantation for patients with AML in first remission","volume":"21","author":"KM Kang","year":"2003","journal-title":"Radiat Oncol J"},{"key":"pone.0261550.ref012","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.3109\/10428194.2014.963080","article-title":"Presentation and outcomes among patients with isolated myeloid sarcoma: a Surveillance, Epidemiology, and End Results database analysis","volume":"56","author":"M Movassaghian","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"pone.0261550.ref013","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000253592","article-title":"Wu KJAh. Prognostic factors of treatment outcomes in patients with granulocytic sarcoma","volume":"122","author":"T-Y Lan","year":"2009","journal-title":"Acta Haematol"},{"key":"pone.0261550.ref014","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.3324\/haematol.2019.223032","article-title":"The prevalence of extramedullary acute myeloid leukemia detected by (18)FDG-PET\/CT: final results from the prospective PETAML trial.","volume":"105","author":"F St\u00f6lzel","year":"2020","journal-title":"Haematologica"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0261550","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T13:29:29Z","timestamp":1640006969000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0261550"}},"subtitle":[],"editor":[{"given":"Domenico","family":"Albano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,12,20]]},"references-count":14,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0261550","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-113048\/v1","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,20]]}}}